 BURLINGAME, Calif., Sept. 07, 2021 GLOBE NEWSWIRE -- ALX Oncology Holdings Inc., ALX Oncology Nasdaq: ALXO a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences. 